Payment overview · 2025
General Payments
$1,294.75
78 reported records · 14 companies
Healthcare provider profile · identity verified
Thomas C Gniadek, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · WATERBURY, CT · NPI 1972591931
Verified facts
What the public records show
CMS Open Payments records show Thomas C Gniadek, M.D. received $1,294.75 in general payments during 2025 across 78 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 16.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 394 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Tresiba by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $216.86 | 16.8% | 14 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $197.88 | 15.3% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $191.04 | 14.8% | 17 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $171.66 | 13.3% | 14 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $100.79 | 7.8% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $95.08 | 7.3% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $79.62 | 6.2% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $64.26 | 5.0% | 3 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $48.92 | 3.8% | 2 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $37.61 | 2.9% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $29.05 | 2.2% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $27.12 | 2.1% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$20.46 | 1.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.40 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,294.75 | 78 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $296.48 | 17 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $197.88 | 10 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $171.66 | 14 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $100.79 | 5 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $75.94 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $75.54 | 9 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $48.92 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $44.97 | 2 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $37.61 | 2 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $37.61 | 2 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $37.61 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $29.05 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $27.12 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.36 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $20.46 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $19.29 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $14.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 104 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 114 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 197 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
197 | 48 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
104 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
104 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
394 | 60 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
114 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 905 | 236 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 434 | 108 |
| Mounjaro | Tirzepatide | 394 | 60 |
| Lisinopril | Lisinopril | 304 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 245 | 60 |
| Amlodipine Besylate | Amlodipine Besylate | 237 | 70 |
| Ezetimibe | Ezetimibe | 232 | 58 |
| Losartan Potassium | Losartan Potassium | 206 | 55 |
| Metformin Hcl | Metformin Hcl | 202 | 57 |
| Synthroid | Levothyroxine Sodium | 197 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 176 | 48 |
| Furosemide | Furosemide | 173 | 53 |
| Pravastatin Sodium | Pravastatin Sodium | 150 | 43 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 142 | 52 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 141 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 139 | 38 |
| Atorvastatin Calcium | Atorvastatin Calcium | 136 | 38 |
| Tresiba Flextouch U-100 | Insulin Degludec | 136 | 38 |
| Gabapentin | Gabapentin | 132 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 131 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 129 | 23 |
| Ozempic | Semaglutide | 114 | 18 |
| Glimepiride | Glimepiride | 112 | 31 |
| Metformin Hcl Er | Metformin Hcl | 111 | 35 |
| Alprazolam | Alprazolam | 110 | 25 |
| Jardiance | Empagliflozin | 104 | 32 |
| Nateglinide | Nateglinide | 94 | 28 |
| Montelukast Sodium | Montelukast Sodium | 90 | 28 |
| Allopurinol | Allopurinol | 80 | 22 |
| Eliquis | Apixaban | 80 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 73 | 26 |
| Potassium Chloride | Potassium Chloride | 73 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 65 | 24 |
| Alendronate Sodium | Alendronate Sodium | 65 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 61 | 18 |
| Tramadol Hcl | Tramadol Hcl | 58 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 57 | 15 |
| Omeprazole | Omeprazole | 55 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 55 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 50 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 50 | 16 |
| Januvia | Sitagliptin Phosphate | 49 | 14 |
| Lidocaine | Lidocaine | 47 | 12 |
| Simvastatin | Simvastatin | 46 | 12 |
| Novolog | Insulin Aspart | 45 | 12 |
| Clonazepam | Clonazepam | 43 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | 12 |
| Humalog | Insulin Lispro | 42 | 14 |
| Novolog Flexpen | Insulin Aspart | 42 | 23 |
| Klor-Con M20 | Potassium Chloride | 41 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | suppressed |
| Repatha Sureclick | Evolocumab | 37 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 35 | 18 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 35 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 35 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | suppressed |
| Lorazepam | Lorazepam | 34 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 11 |
| Sertraline Hcl | Sertraline Hcl | 32 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 31 | 12 |
| Atenolol | Atenolol | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 30 | suppressed |
| Ramipril | Ramipril | 30 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 28 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Methimazole | Methimazole | 27 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 23 | suppressed |
| Prednisone | Prednisone | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 22 | 18 |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Creon | Lipase/Protease/Amylase | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 20 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Famotidine | Famotidine | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Carvedilol | Carvedilol | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 14 | suppressed |
| Tadalafil | Tadalafil | 14 | suppressed |
| Tresiba | Insulin Degludec | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Meloxicam | Meloxicam | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Euthyrox | Levothyroxine Sodium | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Humalog Mix 50-50 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,294.75 · 78 records | Boehringer Ingelheim Pharmaceuticals, Inc. | EVENITY, FREESTYLE LIBRE 3, GLYCATE, GVOKE HYPOPEN, JARDIANCE, LEQVIO, MINIMED 780G, Omnipod, Ozempic, PROLIA, RECORLEV, RELTONE 200 MG, RELTONE 400 MG, REZDIFFRA, SYNTHROID, TEPEZZA, UNITHROID, Wegovy, XYOSTED | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error